Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin during exercise for the prevention of hypoglycaemia in Type 1 diabetes
2017-003911-21Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dapagliflozin in diabetes mellitus type 1 (T1D) and hypoglycaemia, sponsored by University of Oxford. Primary endpoint: Time to hypoglycaemia during exercise challenge. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)hypoglycaemia
Beyond the preview
Go deeper on 2017-003911-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003911-21.